Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis

Conditions:   Breast Cancer;   Brain Metastases, Adult;   Stereotactic Radiosurgery;   Whole Brain Radiotherapy Intervention:   Radiation: Stereotactic Radiosurgery Sponsor:   Postgraduate Institute of Medical Education and Research Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Clin Transl Oncol. 2022 Jan 13. doi: 10.1007/s12094-021-02772-w. Online ahead of print.ABSTRACTPURPOSE: RENORT is an application (app) developed to assess the role of radiotherapy in the treatment of cancer using the oncology information systems (OIS).METHODS/PATIENTS: The RENORT app was used to analyze the data for all patients seen and/or treated at six radiation oncology departments in Spain in 2019. This app can be used to extract the demographic data, treatment sequence, disease status, and radiotherapy treatments from the ARIA and Mosaiq OIS.RESULTS: A total of 6564 treatments were performed at these six centers in 2...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Rom J Morphol Embryol. 2021 Apr-Jun;62(2):435-444. doi: 10.47162/RJME.62.2.09.ABSTRACTThe incidence of brain metastases (BMs) originating in breast cancer (BC) is increasing due to advances in imaging techniques, which can detect such events early, and due to new therapies that can ensure longer survival. We performed a retrospective study on patients with BMs originating in BC and receiving surgical treatment in Neurosurgery Clinics of Prof. Dr. Nicolae Oblu Emergency Clinical Hospital, Iaşi, Romania, from January 2018 to December 2019. We identified 10 consecutive patients who underwent a craniotomy for a BMs originatin...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Authors: Source Type: research
AbstractPurposeRENORT is an application (app) developed to assess the role of radiotherapy in the treatment of cancer using the oncology information systems (OIS).Methods/PatientsThe RENORT app was used to analyze the data for all patients seen and/or treated at six radiation oncology departments in Spain in 2019. This app can be used to extract the demographic data, treatment sequence, disease status, and radiotherapy treatments from the ARIA and Mosaiq OIS.ResultsA total of 6564 treatments were performed at these six centers in 2019. Most patients (56.9%) were males (females 43.1%). The mean patient age was 64.9  ye...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
In this study, we compared the gene expression profiles of the brain metastatic cell line MDA-MB-231-BR (231-BR) and its parental MDA-MB-231, and identified a total of 84 genes in the primary screening through a series of bioinformatic analyses, including construction of protein-protein interaction (PPI) networks by STRING database, identification of hub genes by applying of MCODE and Cytohubba algorithms, identification of leading-edge subsets of Gene Set Enrichment Analysis (GSEA), and identification of most up-regulated genes. Eight genes were identified as candidate genes due to their elevated expression in brain metas...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Our study is based on a large population derived from the Surveillance, Epidemiology, and End Results (SEER) database. The study found that the middle-aged females were at a higher risk of developing brain metastases, while the middle-aged males with brain metastases were at a higher risk of having poorer survival. AbstractBackgroundPopulation-based estimates of the impact of gender throughout the whole course of brain metastases (BMs) at the time of diagnosis of systemic malignancies are insufficient. We aimed to discover the influence of gender on the presence of BMs in newly diagnosed malignancies and the survival of th...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
CONCLUSION: Our study provides an updated population-level estimate of the incidence and survival for patients with brain metastases at the diagnosis of breast cancer, thus may help early identification, prognostic stratification and treatment planning for such patients.PMID:35012859 | DOI:10.1016/j.asjsur.2021.12.037
Source: Asian Journal of Surgery - Category: Surgery Authors: Source Type: research
ConclusionThis study revealed a novel pathway affected by ALDH1A3, GABA metabolism. Like ALDH1A3 expression, GABA treatment promotes metastasis. Given the clinical use of  GABA mimics to relieve chemotherapy-induced peripheral nerve pain, further study of the effects of GABA in breast cancer progression is warranted.
Source: Metabolomics - Category: Biology Source Type: research
Cell Metab. 2022 Jan 4;34(1):90-105.e7. doi: 10.1016/j.cmet.2021.12.001.ABSTRACTHER2+ breast cancer patients are presented with either synchronous (S-BM), latent (Lat), or metachronous (M-BM) brain metastases. However, the basis for disparate metastatic fitness among disseminated tumor cells of similar oncotype within a distal organ remains unknown. Here, employing brain metastatic models, we show that metabolic diversity and plasticity within brain-tropic cells determine metastatic fitness. Lactate secreted by aggressive metastatic cells or lactate supplementation to mice bearing Lat cells limits innate immunosurveillance...
Source: Cell Metabolism - Category: Cytology Authors: Source Type: research
Purpose of review To highlight recent practice changing clinical trials, focusing on those leading to new drug approvals, in human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Recent findings The improved disease-free survival of adjuvant trastuzumab emtansine (T-DM1) over trastuzumab in patients with residual disease has made neoadjuvant sequencing of therapy standard for most patients with early stage disease. In patients with metastatic HER2+ breast cancer, trastuzumab deruxtecan has recently shown dramatically improved efficacy over T-DM1. Tucatinib is an oral tyrosine kinase inhibitor ...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: BREAST CANCER: Edited by Gottfried E. Konecny Source Type: research
Conclusion: Overall, these results indicate that SERPINH1 may serve as an important prognostic biomarker and correlate with tumor immunity in human pan-cancer.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Education | Neurology | Research | Universities & Medical Training